Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Next Previous
Trial Profile

Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agenmestencel-T (Primary) ; Ganciclovir
  • Indications Adenocarcinoma; Gastrointestinal cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms TREAT-ME 1
  • Sponsors Apceth Biopharma

    • Most Recent Events

    • 31 May 2019 Status has been changed to completed.
    • 31 May 2019 Results assessing safety and tolerabilty of genetically modified autologous mesenchymal stromal cells published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 02 Jun 2015 Tolerability results (phase 1) presented at the 51st Annual Meeting of the American Society of Clinical Oncology. No safety concerns to prevent progression to phase II testing.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top